Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor

Science

Volumn 272, Issue 5267, 1996, Pages 1470-1473

  Dobner, Thomas ^a   Horikoshi, Nobuo ^b   Rubenwolf, Susanne ^a   Shenk, Thomas ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TRANSCRIPTION FACTOR; VIRUS PROTEIN;

ADENOVIRUS; AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; TRANSACTIVATION; TRANSCRIPTION TERMINATION; TUMOR SUPPRESSOR GENE;

EID: 0030001373     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.272.5267.1470     Document Type: Article

References (42)

1. S. Fields and S. K. Jang, Science 249, 1046 (1990); R. W. O'Rourke et al., Oncogene 5, 1829 (1990); L. Raycroft, H. Wu, G. Lozano, Science 249, 1049 (1990).
2. S. Fields and S. K. Jang, Science 249, 1046 (1990); R. W. O'Rourke et al., Oncogene 5, 1829 (1990); L. Raycroft, H. Wu, G. Lozano, Science 249, 1049 (1990).
3. S. Fields and S. K. Jang, Science 249, 1046 (1990); R. W. O'Rourke et al., Oncogene 5, 1829 (1990); L. Raycroft, H. Wu, G. Lozano, Science 249, 1049 (1990).
4. W. S. El-Deiry et al., Cell 75, 817 (1993).
5. Reviewed in G. P. Zambetti and A. J. Levine, FASEB J. 7, 855 (1993).
6. C. Prives et al., Cold Spring Harbor Symp. Quant. Biol. 59, 207 (1994).
7. Reviewed in B. Vogelstein and K. W. Kinzler, Cell 70, 523 (1992).
8. A. J. Levine et al., J. Lab. Clin. Med. 124, 817 (1994).
9. H. Lu and A. J. Levine, Proc. Natl. Acad. Sci. U.S.A. 92, 5154 (1995); C. J. Thut, J.-L. Chen, R. Klemm, R. Tjian, Science 267, 100 (1995).
10. H. Lu and A. J. Levine, Proc. Natl. Acad. Sci. U.S.A. 92, 5154 (1995); C. J. Thut, J.-L. Chen, R. Klemm, R. Tjian, Science 267, 100 (1995).
11. J. Momand, G. P. Zambetti, D. C. Olson, D. George, A. J. Levine, Cell 69, 1237 (1992); J. Chen, V. Marechal, A. J. Levine, Mol. Cell. Biol. 13, 4107 (1993); J. D. Oliner et al., Nature 362, 857 (1993).
12. J. Momand, G. P. Zambetti, D. C. Olson, D. George, A. J. Levine, Cell 69, 1237 (1992); J. Chen, V. Marechal, A. J. Levine, Mol. Cell. Biol. 13, 4107 (1993); J. D. Oliner et al., Nature 362, 857 (1993).
13. J. Momand, G. P. Zambetti, D. C. Olson, D. George, A. J. Levine, Cell 69, 1237 (1992); J. Chen, V. Marechal, A. J. Levine, Mol. Cell. Biol. 13, 4107 (1993); J. D. Oliner et al., Nature 362, 857 (1993).
14. P. Sarnow, Y. S. Ho, J. Williams, A. J. Levine, Cell 28, 387 (1982); C. C. Kao, P. R. Yew, A. J. Berk, Virology 52, 456 (1990); P. R. Yew and A. J. Berk, Nature 357, 82 (1992).
15. P. Sarnow, Y. S. Ho, J. Williams, A. J. Levine, Cell 28, 387 (1982); C. C. Kao, P. R. Yew, A. J. Berk, Virology 52, 456 (1990); P. R. Yew and A. J. Berk, Nature 357, 82 (1992).
16. P. Sarnow, Y. S. Ho, J. Williams, A. J. Levine, Cell 28, 387 (1982); C. C. Kao, P. R. Yew, A. J. Berk, Virology 52, 456 (1990); P. R. Yew and A. J. Berk, Nature 357, 82 (1992).
17. T. R. Hupp, D. W. Meek, C. A. Midgley, D. P. Lane, Cell 71, 875 (1992).
18. T. R. Hupp and D. P. Lane, Curr. Biol. 4, 865 (1994).
19. Y. Wang and C. Prives, Nature 376, 88 (1995).
20. I. Takenaka, F. Morin, B. R. Seizinger, N. Kley, J. Biol. Chem. 270, 5405 (1995).
21. R. Brain and J. R. Jenkins, Oncogene 9, 1775 (1994); L. Wu, H. Bayle, B. Elenbaas, N. P. Pavletich, A. J. Levine, Mol. Cell. Biol. 15, 497 (1995).
22. R. Brain and J. R. Jenkins, Oncogene 9, 1775 (1994); L. Wu, H. Bayle, B. Elenbaas, N. P. Pavletich, A. J. Levine, Mol. Cell. Biol. 15, 497 (1995).
23. J. Jayaraman and C. Prives, Cell 81, 1021 (1995).
24. P. Sarnow et al., J. Virol. 49, 692 (1984).
25. SAOS-2, HeLa, or H1299 cells were transfected with 3 μg of a reporter plasmid, p50-2CAT [G. P. Zambetti, J. Bargonetti, K. Walker, C. Prives, A. J. Levine, Genes Dev. 6, 1143 (1992)] or pGalTK-LUC, which contains five Gal4 DNA binding sites upstream of the herpes virus thymidine kinase promoter that controls expression of luciferase, plus various amounts of effector plasmids. Effector plasmids used the cytomegalovirus major immediate early promoter to express p53 (p53); Gal4-p53 fusion proteins, p53 amino acids 1 to 393 (pGalp53), 1 to 52 (pGalp53N), or 80 to 393 (pGalp53C); adenovirus proteins, 55-kD E1B (pE1B-55), E4orf3 (pE4orf3), or E4orf6 (pE4orf6); or Gal4 fusion proteins containing adenovirus 55-kD E1B (pGalE1B-55) or E4orf6 (pGalE4orf6). Cells were harvested 48 hours (luciferase assays) or 72 hours (chloramphenicol acetyltransferase assays) after transfection, and enzyme activities were quantified.
26. N. Horikoshi et al., Mol. Cell. Biol. 15, 227 (1995).
27. P. R. Yew, X. Liu, A. J. Berk, Genes Dev. 8, 190 (1994).
28. GST fusion proteins containing segments of p53 (78) were purified by binding to glutathione-Sepharose, subjected to electorphorssis, and transferred to a nitrocellulose membrane. Protein bound to the nitrocellulose was monitored with the use of Coomassie blue strain. To test for protein interactions, histidine-tagged 55-kD E1B and E4orf6 from baculovirus-infected cells were incubated with the membrane-bound GST fusion proteins, reacted with either an antibody specific to 55-kD E1B (2A6) [P. Sarnow, C. A. Sullivan, A. J. Levine, Virology 120, 510 (1982) ] or an E4orf6-specific antibody, RSA3 [M. J. Marton, S. B. Baim, D. A. Ornelles, T. Shenk, J. Virol. 64, 2345 (1990)], and bound antibodies were detected with a horseradish peroxidase readout (ECL System, Amersham).
29. GST fusion proteins containing segments of p53 (78) were purified by binding to glutathione-Sepharose, subjected to electorphorssis, and transferred to a nitrocellulose membrane. Protein bound to the nitrocellulose was monitored with the use of Coomassie blue strain. To test for protein interactions, histidine-tagged 55-kD E1B and E4orf6 from baculovirus-infected cells were incubated with the membrane-bound GST fusion proteins, reacted with either an antibody specific to 55-kD E1B (2A6) [P. Sarnow, C. A. Sullivan, A. J. Levine, Virology 120, 510 (1982) ] or an E4orf6-specific antibody, RSA3 [M. J. Marton, S. B. Baim, D. A. Ornelles, T. Shenk, J. Virol. 64, 2345 (1990)], and bound antibodies were detected with a horseradish peroxidase readout (ECL System, Amersham).
30. Human MCF7 cells were either mock-infected or infected with adenovirus at a multiplicity of 50 (wt300) or 250 plaque-forming units per cell (d/338 and d/355). Extracts were prepared 36 hours later and subjected to immunoprecipitation with the use of the p53-specific antibody DO-1. Immunoprecipitated proteins were analyzed by protein immunoblot assay with RSA3 antibody.
31. R. J. Grand, M. L. Grant, P. H. Gallimore, Virology 203, 229 (1994).
32. Histidine-tagged E4orf6 purified from baculovirus-infected cells was tested for its ability to inhibit oligomerization of in vitro-translated p53 proteins [E. Shaulian, A. Zauberman, D. Ginsberg, M. Oren, Mol. Cell. Biol. 12, 5581 (1992)] or to influence DNA binding in a band shift assay.
33. II31 fusion protein were analyzed by protein immunoblot assay with a mixture of antibodies to p53 (mAb 421) and E4orf6 (RSA3).
34. J. Milner and E. A. Medcalf, Cell 65, 765 (1991).
35. T. D. Halazonetis, J. Davis, A. N. Kandil, EMBO J. 12, 1021 (1993); T. D. Halazonetis and A. N. Kandil, ibid., p. 5057; J. F. Waterman, J. L. Shenk, T. D. Halazonetis, ibid. 14, 512 (1995).
36. T. D. Halazonetis, J. Davis, A. N. Kandil, EMBO J. 12, 1021 (1993); T. D. Halazonetis and A. N. Kandil, ibid., p. 5057; J. F. Waterman, J. L. Shenk, T. D. Halazonetis, ibid. 14, 512 (1995).
37. T. D. Halazonetis, J. Davis, A. N. Kandil, EMBO J. 12, 1021 (1993); T. D. Halazonetis and A. N. Kandil, ibid., p. 5057; J. F. Waterman, J. L. Shenk, T. D. Halazonetis, ibid. 14, 512 (1995).
38. L. E. Babiss and H. S. Ginsberg. J. Virol. 50, 202 (1984); D. N. Halbert, J. R. Cutt, T. Shenk, ibid. 56, 250(1985); S. Pilder, M. Moore, J. Logan, T. Shenk, Mol. Cell. Biol. 6, 470 (1986); D. H. Weinberg and G. Ketner, J. Virol. 57, 833 (1986).
39. L. E. Babiss and H. S. Ginsberg. J. Virol. 50, 202 (1984); D. N. Halbert, J. R. Cutt, T. Shenk, ibid. 56, 250(1985); S. Pilder, M. Moore, J. Logan, T. Shenk, Mol. Cell. Biol. 6, 470 (1986); D. H. Weinberg and G. Ketner, J. Virol. 57, 833 (1986).
40. L. E. Babiss and H. S. Ginsberg. J. Virol. 50, 202 (1984); D. N. Halbert, J. R. Cutt, T. Shenk, ibid. 56, 250(1985); S. Pilder, M. Moore, J. Logan, T. Shenk, Mol. Cell. Biol. 6, 470 (1986); D. H. Weinberg and G. Ketner, J. Virol. 57, 833 (1986).
41. L. E. Babiss and H. S. Ginsberg. J. Virol. 50, 202 (1984); D. N. Halbert, J. R. Cutt, T. Shenk, ibid. 56, 250(1985); S. Pilder, M. Moore, J. Logan, T. Shenk, Mol. Cell. Biol. 6, 470 (1986); D. H. Weinberg and G. Ketner, J. Virol. 57, 833 (1986).
42. We thank N. Kley, H. Lu, J. Lin, and A. Levine for plasmids, A. Levine for critical reading of the manuscript, J. Gong for able technical assistance, and T.D. thanks H. Wolf for support in Regensberg. This work was supported by grants from NIH (T.S.) and the Infektionsforschung AIDS-Stipendienprogramm DKFZ (T.D.). S.R. received scholarship support from the University of Regensberg, and T.S. is an American Cancer Society Professor and an Investigator of the Howard Hughes Medical Institute.